Celator Pharmaceuticals (NASDAQ: CPXX) is one of 210 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Celator Pharmaceuticals to similar companies based on the strength of its valuation, profitability, institutional ownership, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Celator Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celator Pharmaceuticals N/A -75.03% -46.70%
Celator Pharmaceuticals Competitors -3,959.40% -119.48% -44.27%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Celator Pharmaceuticals and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celator Pharmaceuticals 0 0 0 0 N/A
Celator Pharmaceuticals Competitors 490 2372 6434 121 2.66

As a group, “Biotechnology & Medical Research” companies have a potential upside of 7.34%.

Insider & Institutional Ownership

46.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Celator Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Celator Pharmaceuticals N/A N/A N/A
Celator Pharmaceuticals Competitors $220.75 million -$39.68 million -0.57

Celator Pharmaceuticals’ rivals have higher revenue, but lower earnings than Celator Pharmaceuticals. Celator Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Celator Pharmaceuticals rivals beat Celator Pharmaceuticals on 4 of the 6 factors compared.

Celator Pharmaceuticals Company Profile

Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company’s product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Receive News & Stock Ratings for Celator Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.